WestGene Spearheads Oncology Breakthroughs at the 3rd mRNA-Based Therapeutics Summit

In her keynote, Dr. Song discussed updates and interim data on mRNA-based cancer vaccines targeting EBV-associated cancers and HBV positive liver cancer. She discussed WestGene's breakthroughs in the treatment of specific cancers such as nasopharyngeal carcinoma, NKT lymphoma, HBV-related hepatocellular carcinoma and colorectal cancer, highlighting the safety and efficacy established by the IIT clinical trial data. This speech underscored the transformative impact of WestGene's mRNA therapy in the field of oncology.

In her keynote, Dr. Song discussed updates and interim data on mRNA-based cancer vaccines targeting EBV-associated cancers and HBV positive liver cancer. She discussed WestGene's breakthroughs in the treatment of specific cancers such as nasopharyngeal carcinoma, NKT lymphoma, HBV-related hepatocellular carcinoma and colorectal cancer, highlighting the safety and efficacy established by the IIT clinical trial data. This speech underscored the transformative impact of WestGene's mRNA therapy in the field of oncology.

The EBV-associated cancer vaccine, a prominent project in WestGene's portfolio of over 20 mRNA initiatives, has overcome significant hurdles such as tumor vaccine efficacy and immunogenicity. Its rapid production and cost-effectiveness, coupled with its high efficacy and low toxicity, significantly improve patient accessibility, and provide a more viable treatment option for a broader patient base. This innovation was especially recognized at the 2022 National Disruptive Technology Innovation Competition, where WestGene triumphed as the only winner in the mRNA category among 2,800 entries, cementing its status as a pioneer in the biotech industry in China.

Founded by two visionary scientists, Dr. Wei Yuquan and Dr. Xiangrong Song, WestGene Biotech is dedicated to pioneering the field of mRNA therapeutics. Focusing on the development of avant-garde mRNA therapeutics, the company aims to consolidate its position in the global biopharmaceutical market, backed by its robust technological infrastructure and exclusive intellectual property rights.

2023 marked a year of monumental progress for WestGene, with the acquisition of a U.S. patent for its innovative LNP delivery technology and government approval for a key project in AI-driven mRNA drug design for cancer vaccine development and protein replacement. This project, along with its extensive pipeline, positions WestGene at the forefront of biopharmaceutical innovation and research.

Photo - https://mma.prnewswire.com/media/2325862/WestGene.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/westgene-spearheads-oncology-breakthroughs-at-the-3rd-mrna-based-therapeutics-summit-302043405.html